Specialty pharmaceutical company Collegium Pharmaceutical reached a $2.75 million agreement with the U.S. government to settle 27 pending lawsuits related to the opioid crisis and the company’s sale of Xtampza.

New Mexico agreed to join a proposed nationwide settlement worth up to $21 billion resolving claims that the three largest U.S. drug distributors fueled a deadly opioid epidemic, the state’s attorney general said on December 7.

Members of the Sackler family on December 6 said billions of dollars they collected from Purdue Pharma before the company filed for Chapter 11 was the result of extra cash, not part of a “secret plan” to abuse the bankruptcy system.

Generics giant Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products that contributed to the opioid addiction epidemic that swept across the United States and claimed the lives of hundreds of thousands of people.

Drugmaker Endo International Plc agreed to pay $50 million to resolve lawsuits by New York and two of the state’s largest counties related to the sale and marketing of opioids.

Bausch Health Companies Inc. agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800 percent price hike in 2015.

At least six U.S. states, including Georgia, did not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson – which have been accused of fueling the nation’s opioid epidemic – according to the states’ attorneys general.

Endo International Plc agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced July 22.

A group of state attorneys general unveiled on July 21 a landmark $26 billion settlement with large drug companies for allegedly fueling the deadly nationwide opioid epidemic, but the deal still requires support from thousands of local governments.

With a $26 billion nationwide settlement in sight over claims that the three largest U.S. drug distributors and Johnson & Johnson helped fuel a nationwide opioid epidemic, state and local governments will soon turn their attention to pharmacies and a handful of drugmakers.